The short version
- Why people research itA catecholaminergic and serotonergic activity enhancer for age-related cognitive decline, learning, dopaminergic function and rodent lifespan.
- What the evidence isThere is a database trace of a clinical program that never produced a publication.
- What to watchRacing heart, sweating and tremor together.
How BPAP works
A catecholaminergic/serotonergic activity enhancer (CAE/SAE): it increases the amount of transmitter released per nerve impulse rather than causing release itself. That distinction is the whole class. Amphetamine reverses the transporter and dumps non-vesicular transmitter; BPAP amplifies the vesicular, action-potential-coupled release that is already happening, and does not trigger release on its own. In rat striatal slices the enhancement is mediated by trace amine-associated receptor 1 (TAAR1) — a Gs-coupled, intracellularly located receptor — via increased PKC-mediated phosphorylation, alongside increased VMAT2 loading of vesicles; the effect is reversed by the TAAR1 antagonist EPPTB. The enhancer effect is NOT MAO inhibition and not uptake inhibition: neither clorgyline (MAO-A) nor lazabemide (MAO-B) reproduced it in the same preparation. Separately, and at concentrations six orders of magnitude higher, BPAP is a potent dopamine and norepinephrine reuptake inhibitor (IC50 42 and 52 nM) and a weak serotonin one (640 nM), without amphetamine-like releasing action.
The claim that makes this molecule interesting is not that it releases transmitter — it is that it does not. Amphetamine and its relatives reverse the monoamine transporter and push transmitter out of the terminal whether or not a nerve impulse arrived.
BPAP is what you get when you change the ring and keep the effect. Knoll 1999 reports the lineage explicitly: by changing the aromatic ring in PPAP they built compounds “structurally unrelated to the amphetamines”, and out of 65 newly synthesized compounds a tryptamine-derived structure was selected as the potential successor to selegiline.
- Oral
On the goal map: Catecholamine & dopaminergic drive (Focus, memory & cognition)
Research on BPAP16 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Theoretical — no human has received BPAP in any published study. The record is rat, mouse and cell culture, the lifespan and learning claims come from one laboratory, and the single independent aged-rat replication found no lifespan and no cognitive benefit.
Human clinical evidence
No human being has been given BPAP in any published study. There is no clinical trial, no human pharmacokinetic study, no human safety report and no case series. This is not a compound whose trials failed or whose development stalled after human testing — human testing has not been published at all.
There is a database trace of a clinical program that never produced a publication. AdisInsight carries a drug profile for FPFS 1169, originator Fujimoto Pharmaceutical, recording a highest development status of phase II for Parkinson's disease with the status line 'no development reported', last updated 23 July 2014. FPFS-1169 appears in the peer-reviewed literature as one of the R-enantiomer compounds in this exact benzofuranylpropylamine series (Maruyama 2004), which is why the identification is probable rather than certain. A registry entry is not a result: no trial, outcome or safety data from that program has been published, and the AdisInsight record itself sits behind a subscription so only the summary lines could be read.
No completed human trialThe parent compound's human record does not transfer. Selegiline is a licensed drug with decades of human data, and BPAP is separated from it by design rather than by accident: the whole point of the series was to keep the enhancer effect and discard the MAO-B inhibition (Knoll 1992; Knoll 1999). Whatever is known about selegiline in people is known about a drug whose primary mechanism this one deliberately lacks.
Correlative data
There is no human association data either, and that is worth saying plainly rather than padding this section. No cohort, no observational series, no biomarker correlation in humans exists for this molecule, because it has no documented human exposure to correlate with anything.
The nearest human-adjacent evidence belongs to the enhancer CONCEPT, not to this compound. The concept's human anchor is selegiline, where a dopaminergic enhancer effect has been demonstrated in rat tissue and attributed to TAAR1 agonism, and distinguished from rasagiline — an equally selective MAO-B inhibitor which did not show the enhancer effect and may act as a TAAR1 antagonist (Harsing 2023). That is a genuinely interesting dissociation, and it is a rat-slice result about a human drug, not human data about BPAP.
One correlative observation about the literature itself, which a reader deserves. The enhancer concept, the shuttle-box learning results, the lifespan results, the tumor result and the TAAR1 mechanism come substantially from one research school — Knoll, Miklya, Harsing and colleagues in Budapest, with the Japanese chemistry group around Yoneda and Shimazu. Independent work exists and is mostly the transporter and neuroprotection pharmacology (Shimazu 2003; Maruyama 2004; Hamabe 2000). The one fully independent attempt at the aging claim found the opposite (Ernyey 2023). This is the same structural caution the Vault applies to the Khavinson bioregulators: a real, testable hypothesis, largely unreplicated outside the group that proposed it.
How the mechanism reads
The enhancer mechanism, stated as what it actually claims. BPAP increases the transmitter released per nerve impulse — impulse-propagation-mediated, exocytotic release — without causing release itself. In the isolated rat brainstem it enhanced [3H]-noradrenaline and [3H]-dopamine release at 0.18 micromol/L and [3H]-serotonin at 36 nmol/L, and in discrete brain regions at 10^-12 to 10^-14 M; in vivo it enhanced catecholaminergic and serotonergic activity 30 min after 0.1 microgram/kg subcutaneously, and in the shuttle box it was about 130 times more potent than selegiline at antagonizing tetrabenazine-induced inhibition of performance (Knoll 1999).
Experimental, animal or cellThe cleanest experiment in the file proves the mechanism is not MAO inhibition and not reuptake inhibition. In the same preparation, 50 ng/mL was the most effective concentration for enhancing stimulation-induced noradrenaline and dopamine release and 10 ng/mL for serotonin, while neither clorgyline (MAO-A) nor lazabemide (MAO-B) at 250 ng/mL could significantly increase stimulation-induced release. The authors' conclusion is that enhancement is *'clearly different from influencing uptake or MAO'* (Miklya 2003). That is a control experiment doing real work, and it is the reason this compound is not just another MAO-B inhibitor.
MechanisticTAAR1: what is shown versus what is proposed. Shown, in rat striatal slices: BPAP potentiated vesicular [3H]dopamine release via TAAR1 mediation, did not induce non-vesicular release (which is what methamphetamine did in the same experiment), had its effect potentiated by N-ethylmaleimide, acted through increased PKC-mediated phosphorylation, and increased VMAT2 operation so that vesicles loaded and released more (Harsing 2022). Also shown: the effect is reversed by the TAAR1 antagonist EPPTB, and it is concentration-limited — across 10^-13 to 10^-11 mol/L the curves for both dopamine and GABA release were bell-shaped (Harsing 2025). Proposed, and labeled as such by the authors themselves: that TAAR1 carries two distinct binding sites, one for releasers and one for enhancers, driving different PKC phosphorylation (Harsing 2022); and that the descending limb of the bell curve reflects TAAR1-D2 heterodimerization switching TAAR1 signaling off and D2 signaling on (Harsing 2025). The word the papers use is 'hypothesized' and 'speculated', and this page uses it too.
Experimental, animal or cellThe evidence that 'enhancer' is not one mechanism. 3-F-BPAP, a trifluoropropyl analog, antagonized the enhancer effect of BPAP in the shuttle box while leaving the effects of selegiline and (-)-PPAP unchanged (Knoll 2002). Two enhancer effects that can be pharmacologically separated — a tryptamine-derived one and a phenylethylamine-derived one — which is a much stronger claim than 'these drugs are all enhancers' and is the kind of result that makes a hypothesis testable.
MechanisticTHE FACT THAT REFRAMES THE WHOLE PRODUCT: at attainable concentrations this is a reuptake inhibitor, not an enhancer. In HEK-293 cells expressing the human transporters, BPAP inhibited uptake with IC50 values of 42 +/- 9 nM (dopamine), 52 +/- 19 nM (norepinephrine) and 640 +/- 120 nM (serotonin), and displaced [125I]RTI-55 binding at 16 +/- 2, 211 +/- 61 and 638 +/- 63 nM. Tyramine, but not BPAP, potentiated norepinephrine release — and BPAP inhibited tyramine-induced release, which the authors note *'may block tyramine-induced adverse effects such as hypertensive crisis'* (Shimazu 2003). Set that against the enhancer concentrations above: 10^-8 M versus 10^-14 M is six orders of magnitude. Whatever a person swallowing a measured volume of a 100mcg/mL solution is doing, the concentrations are far closer to the reuptake-inhibition range than to the range where the enhancer effect was described.
MechanisticThe rodent lifespan and learning result, with its numbers and its limits. Male Wistar rats, N = 40 per group, BPAP was more potent than selegiline. The authors' conclusion is that the enhancer effect is what extends life (Knoll 2016). And BPAP had no direct cytotoxic effect on medulloblastoma cells and did not alter the cytotoxicity of temozolomide, cisplatin, etoposide or vincristine, so the proposed route is a brain regulation rather than an anti-tumor action (Knoll 2017).
Experimental, animal or cellTHE RESULT THAT CUTS AGAINST THE PRODUCT, and it is the only independent test of the aging claim. A separate group ran aged Long-Evans male rats, starting at 27 months, through pot-jumping (motor skill learning), the five-choice serial reaction time task (attention), the Morris water maze (spatial learning) and a cooperation task (social cognition). Average lifespan of the population was 36 months. BPAP could not improve cognitive performance; neither could it prolong lifespan. The authors' own candidate explanation is a ceiling effect — dietary restriction and lifelong cognitive engagement had already benefited these animals (Ernyey 2023). It is one study, in a different strain, starting in old age rather than young adulthood, so it is not a clean refutation of (Knoll 2016) — but it is the only attempt from outside the originating school, and it came back negative.
Experimental, animal or cellNeuroprotection, in cells, by two different proposed routes. BPAP protected cultured cortical neurons under serum-free conditions, an effect blocked by the sigma receptor antagonist BD1063, implicating sigma receptors (Hamabe 2000); and it protected human dopaminergic SH-SY5Y cells from apoptosis induced by the endogenous neurotoxin N-methyl(R)salsolinol through stabilization of mitochondrial membrane potential and induction of anti-apoptotic Bcl-2, with potency depending on absolute stereochemistry (Maruyama 2004). BPAP also protected hippocampal neurons from beta-amyloid at 10^-14 M (Knoll 1999). All cell culture, and three different proposed mechanisms of protection, which is a reason to hold each of them loosely.
Experimental, animal or cellBehavioral pharmacology in rodent mood models, with a dissociation worth noting. Acute but not chronic administration reduced immobility in the forced swimming test, while chronic but not acute administration improved impaired social interaction after stress, with the effect attributed to dopaminergic activation; the olfactory-bulbectomized rat model was also used (Tsunekawa 2008). Adaptive picture would predict.
Experimental, animal or cellWith dopamine release implicated and a D1 antagonist (SCH 23390) used to probe it (Shimazu 2001). And the product on sale gives no guidance about which one a measured volume lands in.
Experimental, animal or cell
Sources
- Knoll J, Yoneda F, Knoll B, Ohde H, Miklya I. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. British Journal of Pharmacology 1999;128(8):1723-32 · PMID 10588928
- Yoneda F, Moto T, Sakae M, Ohde H, Knoll B, Miklya I, Knoll J. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Bioorganic & Medicinal Chemistry 2001;9(5):1197-212 · PMID 11377178
- Knoll J, Knoll B, Torok Z, Timar J, Yasar S. The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant. Archives Internationales de Pharmacodynamie et de Therapie 1992;316:5-29 · PMID 1356324
- Knoll J, Miklya I, Knoll B, Yasusa T, Shimazu S, Yoneda F. 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged. Life Sciences 2002;71(17):1975-84 · PMID 12175892
- Magyar K, Lengyel J, Bolehovszky A, Knoll B, Miklya I, Knoll J. The fate of (-)1-(benzofuran-2-yl)-2-propylaminopentane . HCl, (-)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain. European Journal of Drug Metabolism and Pharmacokinetics 2002;27(3):157-61 · PMID 12365195
- Miklya I, Knoll J. Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Life Sciences 2003;72(25):2915-21 · PMID 12697274
- Shimazu S, Tsunekawa H, Yoneda F, Katsuki H, Akaike A, Janowsky A. Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane. European Journal of Pharmacology 2003;482(1-3):9-16 · PMID 14659999
- Shimazu S, Takahata K, Katsuki H, Tsunekawa H, Tanigawa A, Yoneda F, Knoll J, Akaike A. (-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release. European Journal of Pharmacology 2001;421(3):181-9 · PMID 11516435
- Hamabe W, Fujita R, Yasusa T, Yoneda F, Yoshida A, Ueda H. (-)1-(Benzofuran-2-yl)-2-propylaminopentane shows survival effect on cortical neurons under serum-free condition through sigma receptors. Cellular and Molecular Neurobiology 2000;20(6):695-702 · PMID 11100977
- Maruyama W, Yi H, Takahashi T, Shimazu S, Ohde H, Yoneda F, Iwasa K, Naoi M. Neuroprotective function of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, [R-(-)-BPAP], against apoptosis induced by N-methyl(R)salsolinol, an endogenous dopaminergic neurotoxin, in human dopaminergic neuroblastoma SH-SY5Y cells. Life Sciences 2004;75(1):107-17 · PMID 15102525
- Tsunekawa H, Noda Y, Miyazaki M, Yoneda F, Nabeshima T, Wang D. Effects of (R)-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [(-)-BPAP] in animal models of mood disorders. Behavioural Brain Research 2008;189(1):107-16 · PMID 18243357
- Knoll J, Miklya I. Life Sciences 2016;167:32-38 · PMID 27777099
- Knoll J, Baghy K, Eckhardt S, Ferdinandy P, Garami M, Harsing LG Jr, Hauser P, Mervai Z, Pocza T, Schaff Z, Schuler D, Miklya I. A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain. Life Sciences 2017;182:57-64 · PMID 28623006
- Harsing LG, Knoll J, Miklya I. Enhancer Regulation of Dopaminergic Neurochemical Transmission in the Striatum. International Journal of Molecular Sciences 2022;23(15):8543 · PMID 35955676
- Harsing LG, Szenasi G, Feher B, Miklya I. Regulation by Trace Amine-Associated Receptor 1 (TAAR1) of Dopaminergic-GABAergic Interaction in the Striatum: Effects of the Enhancer Drug (-)BPAP. Neurochemical Research 2025;50(2):94 · PMID 39903411
- Harsing LG Jr, Timar J, Miklya I. Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline. International Journal of Molecular Sciences 2023;24(17):13334 · PMID 37686140
- Ernyey AJ, Kassai F, Kozma K, Plangar I, Somfai Z, Miklya I, Gyertyan I. Age-related decline of various cognitive functions in well-experienced male rats treated with the putative anti-aging compound (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine ((-)BPAP). GeroScience 2023; published online 12 June 2023 (doi 10.1007/s11357-023-00821-6) · PMID 37306892
- Knoll J. Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain. CNS Drug Reviews 2001;7(3):317-45 · PMID 11607046
- Shimazu S, Miklya I. Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004;28(3):421-7 · PMID 15093948
BPAP safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Taking an MAO inhibitor, stimulant or serotonergic antidepressant, since it enhances impulse-driven transmitter release.
- Psychosis, bipolar disorder or a history of mania.
- Arrhythmia or uncontrolled high blood pressure.
- Seizure history, since greater transmitter release per impulse lowers the threshold.
- Pregnancy or under 18, because no human has received it in a published study.
What’s expected
- Stronger drive and alertness from more dopamine, noradrenaline and serotonin per nerve impulse.
- Shorter sleep and a faster pulse when the effect runs high.
- Everything here is extrapolated from rodent work.
Watch for
- Racing heart, sweating and tremor together.
- Agitation, paranoia or a sudden surge of unusual energy.
- Persistent insomnia.
Labs that tell you it’s working
- Prolactin: more dopamine release suppresses pituitary prolactin.
- Cortisol: an activated noradrenergic axis can raise the morning value.
- Comprehensive Metabolic Panel: baseline liver and kidney handling for a never-published molecule.
Catecholaminergic and serotonergic activity enhancer: raises transmitter release per impulse rather than causing release; no human trial exists. PMID 10588928 PMID 11377178
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
BPAP FAQ4 common questions
- Is BPAP approved for human use?
- No. BPAP is a research compound. No completed randomized human trial has given it yet.
- What is BPAP researched for?
- A catecholaminergic and serotonergic activity enhancer for age-related cognitive decline, learning, dopaminergic function and rodent lifespan.
- Which labs show whether it's doing anything?
- Prolactin; Cortisol; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for BPAP: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



